Anxiety DisordersAlcohol Use Disorder (AUD)Palliative & End-of-Life DistressSubstance Use Disorders (SUD)Depressive DisordersLSDPsilocybin

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

This review (2018) investigates the models (e.g. medium/high dosage) of psychedelic therapy in both its historical context and possible future directions.

Authors

  • Albert Garcia-Romeu
  • William Richards

Published

International Review of Psychiatry
meta Study

Abstract

Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment of a variety of conditions, often incorporating psychoanalytic concepts prevalent at that time. This work contributed seminal insights regarding how these substances may be employed with efficacy and safety in targeted therapeutic interventions, including the importance of optimizing set (frame of mind) and setting (therapeutic environment). More recently, clinical and pharmacological research has revisited the effects and therapeutic potential of psychedelics utilizing a variety of approaches. The current article provides an overview of past and present models of psychedelic therapy, and discusses important considerations for future interventions incorporating the use of psychedelics in research and clinical practice.

Available with Blossom Pro

Research Summary of 'Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions'

Introduction

The paper situates serotonergic hallucinogens (psychedelics) within a long human history of ceremonial and spiritual use, and contrasts that continuity with a relatively short and politically fraught history of clinical application in Western medicine. Earlier mid-20th century research produced extensive but methodologically heterogeneous clinical work with LSD and related compounds, which hinted at therapeutic potential for conditions such as alcoholism and end-of-life anxiety but suffered from inconsistent controls, inadequate follow-up, and limited use of validated outcome measures. Richards and colleagues set out to provide a concise overview of how 5-HT2A receptor agonist psychedelics have been incorporated into targeted therapeutic interventions, to summarise contemporary models and empirical findings relevant to safety and efficacy, and to highlight practical considerations for screening, preparation, administration, and integration. The paper aims to inform future research and clinical implementation by drawing lessons from historical approaches and recent clinical and neuroscientific studies.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

See Pro PlansAlready have an account? Sign in

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Create Free AccountAlready have an account? Sign in

Study Details

References (113)

Papers cited by this study that are also in Blossom

Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire

Baggott, M. J., Coyle, J. R., Erowid, E. et al. · Drug and Alcohol Dependence (2011)

68 cited
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

Neuroticism is associated with challenging experiences with psilocybin mushrooms

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)

78 cited
Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions

Slevc, L. R., Barrett, F. S., Robbins, H. et al. · Frontiers in Psychology (2017)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

Classic hallucinogens in the treatment of addictions

Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses

Bogenschutz, M. P., Pommy, J. A. · Drug Testing and Analysis (2012)

Regulation of human research with LSD in the United States (1949-1987)

Bonson, K. R. · Psychopharmacology (2017)

Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans

Bonson, K. R. · Neuropsychopharmacology (1996)

112 cited
Show all 113 references
MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder

Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)

Serotonergic psychedelics and personality: A systematic review of contemporary research

Bouso, J. C., Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2018)

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

LSD enhances suggestibility in healthy volunteers

Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)

257 cited
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)

Psychedelics and the essential importance of context

Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)

Pahnke’s ‘Good Friday Experiment’: a long-term follow-up and methodological critique

Doblin, R. · Journal of Transpersonal Psychology (1991)

Pharmacokinetics and concentration-effect relationship of oral LSD in humans

Dolder, P. C., Schmid, Y., Haschke, M. et al. · International Journal of Neuropsychopharmacology (2015)

97 cited
Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)

Flashback: psychiatric experimentation with LSD in historical perspective

Dyck, E. · Canadian Journal of Psychiatry (2005)

The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization

Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)

Enhancement of Creative Expression and Entoptic Phenomena as After-Effects of Repeated Ayahuasca Ceremonies

Frecska, E., Móré, C. E., Vargha, A. et al. · Journal of Psychoactive Drugs (2012)

79 cited
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)

594 cited
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers: results of an experimental double-blind placebo-controlled study

Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E. et al. · Psychopharmacology (1999)

141 cited
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)

393 cited
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Griffiths, R. R. · Journal of Psychopharmacology (2008)

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

DPT as an adjunct in psychotherapy of alcoholics

Grof, S., Soskin, R. A., Richards, W. A. et al. · Pharmacopsychiatry (1973)

Psychedelic Agents in Creative Problem-Solving: A Pilot Study

Harman, W. W., McKim, R. H., Mogar, R. E. et al. · Psychological Reports (1966)

Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology

Hartogsohn, I. · Journal of Psychopharmacology (2016)

Constructing drug effects: a history of set and setting

Hartogsohn, I. · Drug Science Policy and Law (2017)

389 cited
The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity

Hartogsohn, I. · Frontiers in Human Neuroscience (2018)

Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision

Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)

89 cited
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
The relationships of classic psychedelic use with criminal behavior in the United States adult population

Hendricks, P. S., Crawford, M. S., Cropsey, K. L. et al. · Journal of Psychopharmacology (2017)

How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2009)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use

Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)

117 cited
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

Johnson, M. W., Maclean, K. A., Reissig, C. J. et al. · Drug and Alcohol Dependence (2011)

132 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Powerful substances in tiny amounts An interview study of psychedelic microdosing

Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)

121 cited
LSD enhances the emotional response to music

Kaelen, M., Barrett, F. S., Roseman, L. et al. · Psychopharmacology (2015)

The hidden therapist: evidence for a central role of music in psychedelic therapy

Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)

213 cited
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation

Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)

138 cited
Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers

Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research

Krupitsky, E. M., Grinenko, A. Y. · Journal of Psychoactive Drugs (1997)

LSD-induced entropic brain activity predicts subsequent personality change

Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)

292 cited
Alterations of consciousness and mystical-type experiences after acute LSD in humans

Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)

190 cited
A clinical study of LSD treatment in alcoholism

Ludwig, A., Levine, J., Stark, L. et al. · American Journal of Psychiatry (1969)

158 cited
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences

Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)

Treatment of alcoholism using psychedelic drugs: a review of the program of research

Mangini, M. · Journal of Psychoactive Drugs (2011)

Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges

McKenna, D. · ACS Chemical Neuroscience (2004)

316 cited
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Grob, C. S., Mithoefer, M. C., Brewerton, T. D. · Lancet Psychiatry (2016)

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)

Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model

Nau, F., Miller, J., Saravia, J. et al. · American Journal of Physiology (2015)

Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens

Nichols, D. E. · Journal of Psychoactive Drugs (1986)

536 cited
Psychedelics as Medicines: An Emerging New Paradigm

Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)

Effects of Schedule I drug laws on neuroscience research and treatment innovation

King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)

A review of the clinical effects of psychotomimetic agents

Osmond, H. · Annals of the New York Academy of Sciences (2010)

296 cited
The psychedelic mystical experience in the human encounter with death

Pahnke, W. N. · Psychedelic Review (1969)

The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network

Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)

The pharmacology of lysergic acid diethylamide: a review

Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)

Developing Guidelines and Competencies for the Training of Psychedelic Therapists

Phelps, J. · Journal of Humanistic Psychology (2017)

The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation

Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)

Effects of serotonin 2A/1A receptor stimulation on social exclusion processing

Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)

Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics

Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)

The Phenomenology and Potential Religious Import of States of Consciousness Facilitated by Psilocybin

Richards, W. A. · Archive for the Psychology of Religion (2008)

Psychedelic Psychotherapy Insights From 25 Years of Research

Richards, W. A. · Journal of Humanistic Psychology (2016)

LSD-assisted psychotherapy and the human encounter with death

Goodman, L. E., Grof, S., Kurland, A. A. et al. · Journal of Transpersonal Psychology (1972)

The peak experience variable in DPT-assisted psychotherapy with cancer patients

Richards, W. A., Rhead, J. C., Dileo, F. B. et al. · Journal of Psychedelic Drugs (1997)

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)

229 cited
Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial

Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)

Psychedelics in the treatment of unipolar mood disorders: a systematic review

Rucker, J., Young, A. H., Jelen, L. A. et al. · Journal of Psychopharmacology (2016)

Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities

Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study

Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)

380 cited
The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports

Sanz, C., Zamberlan, F., Erowid, E. et al. · Frontiers in Neuroscience (2018)

Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Long-lasting subjective effects of LSD in normal subjects

Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)

Is it time to revisit the role of psychedelic drugs in enhancing human creativity?

Sessa, B. · Journal of Psychopharmacology (2008)

MDMA and PTSD treatment:“PTSD: from novel pathophysiology to innovative therapeutics”

Sessa, B. · Neuroscience Letters (2016)

Response of cluster headache to psilocybin and LSD

Sewell, R. A. · Neurology (2006)

Genuine and drug-induced synesthesia: a comparison

Sinke, C., Halpern, J. H., Zedler, M. et al. · Consciousness and Cognition (2012)

Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities

Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)

Increased Activation of Indirect Semantic Associations under Psilocybin

Spitzer, M., Thimm, M., Hermle, L. et al. · Biological Psychiatry (1996)

90 cited
Adverse Reactions to Psychedelic Drugs - A Review of the Literature

Strassman, R. J. · Journal of Nervous and Mental Disease (1984)

273 cited
Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects

Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)

252 cited
Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans

Strassman, R. J., Qualls, C. R., Berg, L. M. · Biological Psychiatry (1996)

118 cited
Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress

Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)

130 cited
Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

Increased global functional connectivity correlates with LSD-induced ego dissolution

Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)

Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada

Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis

Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use

Walsh, Z., Hendricks, P. S., Smith, S. et al. · Journal of Psychopharmacology (2016)

58 cited
Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression

Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)

Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample

Winstock, A. R., Kaar, S., Borschmann, R. · Journal of Psychopharmacology (2013)

89 cited

Cited By (42)

Papers in Blossom that reference this study

Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics

Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)

1 cited
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

Mertens, L. J., Koslowski, M., Betzler, F. et al. · JAMA Psychiatry (2026)

A Transformative Trip? Experiences of Psychedelic Use

Neitzke-Spruill, L., Beit, C., Robinson, J. et al. · Neuroethics (2024)

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression

Szigeti, B., Weiss, B., Rosas, F. E. et al. · Psychological Medicine (2024)

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)

24 cited
Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists

Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

Peck, S. K., Shao, S., Grue, T. et al. · Nature Medicine (2023)

Harnessing placebo: Lessons from psychedelic science

Pronovost-Morgan, C., Hartogsohn, I., Ramaekers, J. G. · Journal of Psychopharmacology (2023)

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

Ley, L., Holze, F., Arikci, D. et al. · Neuropsychopharmacology (2023)

138 cited
Show all 42 papers
Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review

Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)

4 cited
On the need for metaphysics in psychedelic therapy and research

Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)

Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)

Psychedelic-supportive psychotherapy: A psychotherapeutic model for, before and beyond the medicine experience

Wolfson, P. E. · Journal of Psychedelic Studies (2023)

Psychedelic Identity Shift: A Critical Approach to Set And Setting

Devenot, N., Seale-Feldman, A., Smith, E. et al. · Kennedy Institute of Ethics Journal (2022)

28 cited
Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy-A systematized review

Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial

Baumann, S., Carhart-Harris, R. L., Nutt, D. J. et al. · Psyarxiv (2022)

Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience

Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)

35 cited
Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada

Argento, E., Goldenberg, S., Deering, K. et al. · Drug and Alcohol Dependence (2022)

4 cited
Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default

Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)

Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers

Thal, S., Engels, L. B., Bright, S. J. · Journal of Humanistic Psychology (2022)

Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature

Golden, T. L., Magsamen, S., Sandu, C. C. et al. · Current Topics in Behavioral Neurosciences (2022)

A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development

Whitfield, H. J. · Frontiers in Psychiatry (2021)

Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead

Williams, M. L., Korevaar, D., Harvey, R. et al. · Frontiers in Psychiatry (2021)

16 cited
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy

Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)

Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy

Yehuda, R., Lepow, L., Morishita, H. · Frontiers in Neuroscience (2021)

Cancer Healthcare Workers' Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation

Reynolds, L. M, Stack, A., Akroyd, A., Sundram, F. et al. · International Journal of Environmental Research and Public Health (2021)

22 cited
A Nationwide Study Comparing Mental Health Professionals' Willingness to Try Hallucinogenic Drugs in Basic Research or Clinical Practice

Ginati, Y. D., Ben-Sheetrit, J., Lev-Ran, S. et al. · Journal of Psychoactive Drugs (2021)

5 cited
Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample

Mans, K., Kettner, H., Erritzoe, D. et al. · Frontiers in Psychiatry (2021)

Psilocybin and MDMA for the treatment of trauma-related psychopathology

Bird, C. I. V., Modlin, N. L., Rucker, J. · International Review of Psychiatry (2021)

Psychedelic medicalization, public discourse, and the morality of ego dissolution

Gearin, A. K., Devenot, N. · International Journal of Cultural Studies (2021)

The Potential Role of Psychedelic Drugs in Mental Health Care of the Future

Gründer, G., Jungaberle, H., Gründer, G. · Pharmacopsychiatry (2021)

Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review

Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)

60 cited
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)

On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review

Zeifman, R. J., Singhal, N., Breslow, L. et al. · ACS Pharmacology and Translational Science (2021)

Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy

Strickland, J. C., Garcia-Romeu, A., Johnson, M. W. · ACS Pharmacology and Translational Science (2020)

Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review

DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)

Are Psychedelics Something New in Teaching Psychopharmacology?

Louie, A. K., Beresin, E. V., Coverdale, J. et al. · Academic Psychiatry (2020)

Natural Psychoplastogens As Antidepressant Agents

Benko, J., Vranková, S. · Molecules (2020)

Psychedelics and Psychedelic-Assisted Psychotherapy

Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)

Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance

Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)

Reported effects of psychedelic use on those with low well-being given various emotional contexts

Mason, N. L., Dolder, P. C., Kuypers, K. P. C. · Drug Science Policy and Law (2020)

12 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

See Pro PlansSign in
Current perspectives on psychedelic therapy: use... — Research Summary & Context | Blossom